Analysis of CD95 and CCR7 expression on circulating CD4⁺ lymphocytes revealed disparate immunoregulatory potentials in systemic lupus erythematosus

Alia M. Aldahlawi a,c,*, Mohamed F. Elshal b,f, Laila A. Damiaiti a, Laila H. Damanhori d, Sami M. Bahlas e

a Biological Sciences Department, King Abdulaziz University, Jeddah, Saudi Arabia
b Biochemistry Department – Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
c Immunology Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
d Laboratory Technology Department – Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
e Rheumatology Unit, Internal Medicine Department – Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
f Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute, Sadat City University, Egypt

Received 6 March 2015; revised 3 May 2015; accepted 4 May 2015
Available online 12 May 2015

KEYWORDS
Systemic lupus erythematosus; Apoptosis; Disease activity; CD95; Chemokine receptor; CCR7; Flow cytometry

Abstract Emerging data have implicated a critical role for CD4 in the pathogenesis of systemic lupus erythematosus (SLE). This study was designed to delineate the contribution of CD4⁺ T cells in the pathogenesis of SLE disease. Forty-four patients (3 male: 41 female) and 20 healthy volunteers (4 male: 16 female) were included in the study. CD4⁺ lymphocytes analysis was done using three-color flow cytometry with antibodies against human-CD95, a prototype cell death receptor, and the chemokine receptor-7 (CCR7) after gating for lymphocytes based on the forward and side scatter. Serum levels of IL-6, IL-12, IL-17, TNF-α and IL-10 cytokines were assayed using ELISA. Disease activity was assessed using the SLE disease activity index (SLEDAI). Based on the expression of CCR7 and CD95, CD4⁺ lymphocytes were subdivided into three particular subsets; CD4⁺CD95⁺CCR7⁺ cells, CD4⁺CD95⁺CCR7⁺ cells and CD4⁺CD95⁺CCR7⁻ cells. Percentage of CD4⁺CD95⁺CCR7⁺ cell subset was significantly higher in patients with SLE with
1. Introduction

Systemic lupus erythematosus (SLE) is one of the most common autoimmune diseases that can affect multiple organs and body systems. The etiology of the disease remains unclear; however, it is thought to be triggered by autoantigens that induce autoantibody production. Apoptotic lymphocytes may be one source of autoantigens, and increased numbers of apoptotic lymphocytes have been reported in SLE (Shah et al., 2011). Notably, apoptotic CD4⁺, but not CD8⁺, T lymphocytes were found to constitute the main source for the activated lymphocyte derived DNA and other apoptotic cellular constituents that function as autoantigens to induce production of anti-double-stranded DNA (anti-dsDNA) antibodies in SLE (Wen et al., 2012).

Several studies reported increased levels of apoptotic CD4⁺ lymphocytes in SLE patients; these lymphocytes are characterized by the expression of CD95, (Fas/APO-1), the prototypic death receptor of the immune system (Bijl et al., 2001; Xue et al., 2006). CD95 is a member of the TNF receptor superfamily, whose ligand, CD95L (FasL), is expressed on activated; but not resting T cells (Garrone et al., 1995; Genestier et al., 1998). In addition to its role in apoptosis, CD95 binding to its agonist was found to activate the nuclear factor-kappa B (NF-κB), a transcriptional factor that plays critical roles in inflammation, immunity, cell proliferation, differentiation, and survival (Rensing-Ehl et al., 1995). NF-κB is involved in the transcriptional regulation of many cytokine (Rensing-Ehl et al., 1995), and chemokine (Liu et al., 2004; Tang et al., 2009) genes expressed in activated lymphocytes. Thus, in addition to provoking apoptosis, CD95 receptor stimulation can indirectly trigger inflammation and lymphocyte migration to lymph nodes or inflamed peripheral tissues (Cullen et al., 2013).

In essence, the interaction between T-B lymphocytes occurring in lymphoid tissues requires the migration of T and B-cells to their specified T- and B-cell zones in lymphoid tissue where they encounter dendritic cells and antigens (Eriksson and Rantapaa-Dahlqvist, 2014). This process depends on migration of CD4⁺ T cell to secondary lymphoid organs and the multitude of autoantigens that can provide. Previous investigations show that CD4⁺ T cells expressing the chemokine receptor-7 (CCR7), which recognizes CCL19 and CCL21, are attracted close to B cell follicles where it triggers the activation and differentiation (T-cell help) of B cells in germinal centers of the lymphoid tissue (MacLennan, 1994; Okada and Cyster, 2006).

The aforementioned data suggest that the surface receptor CD95 is involved in other physiological functions besides apoptotic signaling, such as inflammation cytokine and/or chemokine receptor expression. Therefore, we aimed to investigate the extent of CD4⁺ lymphocytes expressing CD95 and their association with chemokine receptor CCR7 expression, inflammatory cytokines and disease activity in patients with SLE.

2. Materials and methods

2.1. Patients

A total of 44 SLE patients were classified according to the SLE disease activity index (SLEDAI) (Bombardier et al., 1992), into active group defined as SLEDAI score > 6 (included 3 males and 23 Females) patients, and inactive group defined as SLEDAI score less than 6 (included 18 females). Twenty healthy volunteers (4 males and 16 females), who were clinically and laboratory free of any autoimmune diseases, served as a control group. All patients have provided written informed consent for study inclusion and the anonymous use of their data from lupus disease registry. The King Abdulaziz University Hospital Ethics Committee has approved the study.

2.2. Clinical and laboratory assessments

Clinical and demographic characteristics were recorded for all patients shown in (Table 1). Levels of anti-nuclear antibodies (ANA), anti-dsDNA antibody, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), complete blood count (CBC), complement (C)-3, C4, urine analysis were assayed using commercially available kits according to the manufacturer's instructions.

2.3. Flow cytometry analysis

Peripheral blood mononuclear cells (PBMCs) were analyzed by three-color flow cytometry using CD95-FITC, CCR7-PE, and
Table 1: Demographic, clinical and laboratory data for the studied groups.

| Parameters                     | Active SLE (n = 26) | Inactive SLE (n = 18) | HCs (n = 20) |
|--------------------------------|---------------------|-----------------------|--------------|
| **Demographic and clinical data** |                     |                       |              |
| Gender (male/female)           | 3/23                | 0/18                  | 4/16         |
| Age (years)                    | 35.44 ± 11.36       | 31.81 ± 10.21         | 29.15 ± 4.74 |
| Disease duration (years)       | 5.88 ± 5.99         | 4.86 ± 1.43           |              |
| SLEDAI                         | 15.57 ± 7.69        | 3.5 ± 2               |              |
| **Laboratory data**            |                     |                       |              |
| IL-6 (ng/ml)                   | 9.55 ± 2.23         | 9.72 ± 1.91           | 3.47 ± 1.41  |
| IL-12 (ng/ml)                  | 21.59 ± 1.66        | 22.71 ± 0.67          | 15.42 ± 1.16 |
| TNF-α (ng/ml)                  | 19.49 ± 2.18        | 16.83 ± 1.54          | 8.99 ± 0.47  |
| IL-17 (ng/ml)                  | 41.65 ± 2.13        | 33.53 ± 2.11          | 27.47 ± 1.29 |
| IL-10 (ng/ml)                  | 21.9 ± 2.43         | 19.27 ± 2.33          | 13.83 ± 1.35 |
| ANA (IU/ml)                    | 0.75 ± 0.33         | 0.53 ± 0.39           | 0.11 ± 0.04  |
| Anti ds-DNA (IU/ml)            | 665.85 ± 401.2      | 445.52 ± 217.44       | Neg.         |
| C3 (g/L) (0.75–1.65)           | 0.84 ± 0.32         | 0.93 ± 0.34           | 0.78 ± 0.14  |
| C4 (g/L) (0.2–0.6)             | 0.14 ± 0.43         | 0.16 ± 0.09           | 0.29 ± 0.07  |
| CRP (mg/L)                     | 4.85 ± 2.16         | 4.99 ± 3.57           | 2.46 ± 0.19  |
| ESR (mm/H)                     | 25.64 ± 16.25       | 26.81 ± 13.21         | 11.8 ± 6.25  |
| WBC (K/UL)                     | 3.35 ± 1.58         | 5.57 ± 1.26           | 8.64 ± 2.99  |
| RBC (M/UL)                     | 4.50 ± 0.69         | 4.27 ± 0.72           | 4.52 ± 0.47  |
| PLT (K/UL)                     | 279.07 ± 68.16      | 243.13 ± 67.05        | 268.4 ± 71.02|
| WBC in urine                   | 9.43 ± 6.13         | 2.24 ± 2.41           | –            |
| RBC in urine                   | 8.71 ± 7.87         | 2.24 ± 2.12           | –            |

Values represent mean ± S.D. of means. Superscript letter “a” refers to significant difference in comparison with control group, and “b” with inactive SLE group. The difference is significant at \( P < 0.05 \) levels.

CD4-PerCP. Isotype-matched control mAbs were used to determine the nonspecific binding. All monoclonal antibodies were purchased from R&D system (Minneapolis MN, USA). Flow cytometry analysis was performed on BD FACSCalibur™ flow cytometer and 10,000 events were acquired using Cell Quest Software (BD Biosciences, San Jose, CA, USA). Data were analyzed with the Summit v4.3 Build 2445 software (Dako Colorado Inc., Fort Collins, CO, USA). Percentages of apoptotic CD4 lymphocytes were determined after gating on the forward scatter and side scatter properties of lymphocytes and the CD4-PerCP positive population (Fig. 1).

2.4. Cytokine measurement

Serum concentrations of pro-inflammatory (IL-6, IL-12, IL-17 and TNF-α) and anti-inflammatory (IL-10) cytokines were assayed by using commercial ELISA kits (ELISA MAX™ Deluxe Sets, BioLegened; San Diego CA, USA). All measurements were performed in duplicate according to the manufacturer’s recommendations.

2.5. Statistical analysis

All data were statistically analyzed using Statistical Package for Social Sciences (SPSS) V20.0. The data were expressed as means ± standard deviation (SD). Correlations were done using Pearson tests, and analyses of variance were done using ANOVA test followed by Bonferroni correction. \( P \)-value less than or equal to 0.05 is considered as being statistically significant.

3. Results

Table 1 presents the demographic, clinical and laboratory data for the studied groups. It is apparent that there is a significant difference \( (P = 0.0001) \) in SLEDAI between active and inactive groups, whereas, the differences in age and number of abortions and pregnancies (in female patients) and disease duration did not show statistical significance.

The concentrations of TNF-α and IL-17 were significantly higher in the active SLE group than that of inactive SLE \( (P = 0.05, P = 0.02 \) respectively) and healthy \( (P = 0.01, P = 0.001 \) respectively) subjects. Whereas the concentrations of IL-6, IL-10 and IL-12 cytokines were significantly higher in both active and inactive SLE patients compared with healthy controls (Table 1).

Expression of CD95 and CCR7 was analyzed on CD4+ T cells that yield three subsets of CD4+ T-cells (Fig. 1). The first subset consists of CD4+CD95+CCR7+ cells which were found significantly higher in active and inactive SLE patients than the healthy control group \( (43 ± 2.7\% \) and \( 42 ± 2.2 \% vs. 13 ± 1.4 \%, P < 0.0001) \). The second cell population includes CD4+CD95−CCR7− cells which were significantly higher in active \( (29 ± 7.2\% \) than inactive \( (21.9 ± 5.6\% \) and healthy \( (18 ± 4.8\% \) \( (P = 0.05 \) and 0.01 respectively). The third CD4+CD95−CCR7− T cell population was significantly higher in control subjects than that in the active SLE group and the inactive SLE group \( (49 ± 5.1\% vs. 28 ± 13.2\% and 31 ± 11.45\%, both at P < 0.05) \) (Fig. 1).

The correlations of each CD4+ T cell subset with other clinical and biochemical parameters are presented in Table 2. CD4+CD95+CCR7+ cells showed a positive correlation with IL-10 and ANA \( (r = 0.499, P = 0.01; r = 0.757, P = 0.001 \) respectively), and a negative correlation with blood WBCs count \( (r = -0.462, P = 0.05) \). CD4+CD95−CCR7− cells correlated positively with number of abortions, SLEDAI, IL-6 and IL-17 concentrations \( (r = 0.465, P = 0.02; r = 0.608, P = 0.001; r = 0.595, P = 0.01 \) and \( r = 0.770, P = 0.001 \) respectively). Whereas, CD4+CD95−CCR7− cells correlated...
negatively with IL-10, IL-17 and TNF-α concentrations ($r = -0.595, P = 0.01; r = -0.587, P = 0.02; r = -0.410, P = 0.05$, respectively, (Table 2).

4. Discussion

The clinical course of SLE disease is heterogeneous with alternating flares periods of increased disease activity and remissions, when pain and inflammation disappear. The reasons behind this fluctuation in disease activity are unclear; however evidence suggests that apoptotic lymphocytes likely account for this phenomenon. As apoptotic lymphocytes, particularly CD4$^+$ lymphocytes, were found to serve as a source for autoantigens and increase the production of ANA and anti-dsDNA antibodies that are considered hallmarks of SLE (Wen et al., 2012).

In the present study, we found that SLE patients had an increased percentage of CD4$^+$ lymphocytes expressing CD95, the prototype marker of apoptosis, indicating an increased apoptosis of these cells in SLE patients in vivo. This finding confirms earlier observations of Wen et al. (2012) that CD95 is upregulated upon activation in SLE. Other studies reported that T cells with increased CD95 antigen expression might be highly susceptible to apoptotic cell death in vivo (Amasaki et al., 1995; Silvestris et al., 2002).

Cell death of CD4 lymphocytes by apoptosis represents a putative mechanism for providing an excessive load of apoptotic particles containing nuclear antigens or of immune complexes containing autoantigens that can overcome self-tolerance mechanisms and trigger autoimmunity (Gabler et al., 2003). However, this seems to depend on two processes, CD4$^+$ T cell activation and migration to secondary lymphoid

Figure 1  (A–C) Example of the gating strategy used to identify CD4$^+$ T cell-subsets according to expressing of CD95 and CCR7. Gates were set around lymphocytes, as defined by forward and side light scatter (A), and then gating on CD4$^+$ bright positive cells (B). The two gates were applied to the lower dot plot (C) displaying CCR7 and CD95.
CD4+ T cell subsets and clinical parameters in studied groups.

| Parameter          | CD4+ CD95+CCR7+ | CD4+ CD95−CCR7− | CD4− CD95−CCR7+ |
|--------------------|-----------------|-----------------|-----------------|
| **Demographic & clinical data** |                 |                 |                 |
| Age                | 0.192           | −0.089          | −0.302          |
| No. pregnancy      | −0.063          | 0.224           | −0.402          |
| No. Of abortion    | −0.306          | 0.456*          | −0.013          |
| Disease duration   | −0.001          | 0.040           | −0.221          |
| SLEDAI             | −0.244          | 0.608**         | −0.256          |
| **Laboratory data** |                 |                 |                 |
| IL-6               | −0.233          | 0.595*          | −0.164          |
| IL-10              | 0.499*          | −0.127          | −0.595*         |
| IL-12              | 0.383           | 0.164           | −0.131          |
| IL-17              | −0.304          | 0.770**         | −0.587*         |
| TNF-alpha          | 0.341           | 0.341           | −0.410*         |
| ANA                | 0.757**         | 0.302           | −0.123          |
| dsDNA              | 0.246           | 0.260           | 0.047           |
| C3                 | 0.008           | 0.203           | −0.097          |
| C4                 | 0.172           | −0.119          | −0.125          |
| CR-P               | 0.027           | 0.097           | −0.011          |
| ESR                | 0.023           | 0.346           | −0.253          |
| WBCs               | −0.490          | −0.124          | 0.270           |
| RBs                | −0.359          | 0.201           | −0.403          |
| PLT                | −0.183          | 0.099           | −0.190          |
| WBC (urine)        | −0.327          | 0.182           | −0.230          |
| RBC (urine)        | 0.054           | 0.012           | −0.092          |
| Total protein      | −0.329          | 0.258           | 0.123           |

**Correlation is significant at the 0.01 level (2-tailed).**

*Correlation is significant at the 0.05 level (2-tailed).

organisms where they can interact with B-cells and dendritic cells. Previous investigations showed that T-helper lymphocytes expressing the chemokine receptor CCR7, which recognizes CCL19 and CCL21 chemokines, are attracted close to B cell follicles where it triggers the activation and differentiation of B cells in germinal centers of lymphoid tissue (Okada and Cyster, 2006; Sallusto et al., 2000).

In our study, the expression of CCR7 and CD95 on CD4+ lymphocytes identified three particular subsets that are CD4+CD95+CCR7+ cells, CD4+CD95−CCR7− cells, and CD4−CD95−CCR7− cells. CD4+CD95+CCR7+ cells subset was found significantly increased in the blood of both active and inactive SLE patients in comparison to healthy individuals. This cell subset showed a significant positive correlation with serum IL-10 cells and ANA titer (P = 0.04 and 0.004 respectively). IL-10 is a cytokine mainly produced by B cells, which use it to support their activation and antibody production (Tyrrell-Price et al., 2001; Xu et al., 2004). This may explain our finding of the concomitant positive correlation between IL-10 and ANA titer and their association with SLEDAI.

In their study of the different types of CD4+ cell subsets; Sallusto et al. (1999) found that a subset of CD4+ cells that express CCR7+ home to the T cell areas of lymphoid organs where they readily proliferate and differentiate into effector cells, marked by the downregulation of CCR7. Recently, this subset of effector CD4+CCR7+ T cells was found migrate to inflamed tissues and display immediate effector functions (Sallusto et al., 2014). In addition, it was found that lack of CCR7 associated with the manifestation of spontaneous autoimmunity (Forster et al., 2008). Furthermore, Kuwabara et al. (2009) demonstrated that a large proportion of CCR7− cells is Th17 population that home to inflamed tissues and secretes inflammatory cytokines mainly IL-17, IL-6 and TNF-α in autoimmune encephalomyelitis. In line with these data, our results showed that CD4+CD95−CCR7− T cells correlated positively with signs of inflammation including number of recurrent spontaneous abortions in female patients and SLEDAI (P < 0.033 and 0.005 respectively). In addition, this cell subset showed significant positive correlations with pro-inflammatory cytokines IL-6 and IL-17 (P < 0.012 and 0.003 respectively).

IL-17 is an essential cytokine in the pathogenesis of SLE, particularly in the development of tissue damage (Apostolidis et al., 2011). Increased production IL-17 in patients with SLE was found to amplify the immune response by augmenting the production of antibodies by B cells (Crispin and Tsokos, 2010). Th17 cells were found increasing target-organ inflammation by producing several kinds of inflammatory cytokines in addition to IL-17, including TNF-α and IL-6 that may exacerbate SLE disease activity (Rana et al., 2012). The positive correlation between CD4+CD95−CCR7− cells and IL-17 in the present study may explain their association with various clinical manifestations of inflammation, and disease activity as manifested by SLEDAI.

The third subset of cells we found is CD4−CD95−CCR7− lymphocytes, which showed a significant higher percentage in healthy subjects, compared with SLE groups. This subset of cells showed a significant negative correlation with IL-10 (P < 0.026), IL-17 (P < 0.012), and TNF-α (P < 0.029), that may suggest their involvement in anti-inflammatory response. These data are in line with previous studies which reported...
that higher levels of naive and lower levels of memory CD4+ T-cells are associated with a more anti-inflammatory profile (Gordon et al., 1996; Ugarte-Gil et al., 2014). The persistence of autoreactive memory cells is thought to be involved in the repeated cycles of remission and recurrent inflammation in SLE (Alecsandru et al., 2011; Leiva et al., 2013).

In conclusion, the present results suggest profound differences between the two CD4+ cell subsets according to the expression of CD95 and CCR7. One subset CD4+CD95+CCR7+ might have a role inactivation of humoral immune response and increasing ANA titer in one hand, whereas CD4+CD95−CCR7− cells subset seem to be involved in inflammatory response and disease activity as indicated by association with inflammatory cytokines IL-17 and IL-6. Taken together, our results suggest that both CD4+CD95+ cell subsets expressing and lacking the expression of CCR7 have variable roles in the pathophysiology of SLE. A better understanding of the characteristics of these cells may shed light on the pathogenesis of autoimmune diseases, particularly SLE.

References

Alecsandru, D., Valor, L., Sanchez-Ramon, S., Gil, J., Carbune, J., Navarro, J., Rodriguez, J., Rodriguez-Sainz, C., Fernandez-Cruz, E., 2011. Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome. Clin. Exp. Immunol. 164, 100–107.

Amasaki, Y., Kobayashi, S., Takeda, T., Ogura, N., Jodo, S., Nakabayashi, T., Tsutsumi, A., Fujisaku, A., Koike, T., 1995. Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia. Clin. Exp. Immunol. 99, 245–250.

Apostolidis, S.A., Crispin, J.C., Tsokos, G.C., 2011. IL-17-producing T cells in lupus nephritis. Lupus 20, 120–124.

Bijl, M., Horst, G., Limburg, P.C., Kallenber, C.G., 2001. Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus. 10, 866–872.

Bombardier, C., Gladman, D.D., Urowitz, M.B., Caron, D., Chang, C.H., 1992. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognostic studies in SLE. Arthritis Rheum. 35, 630–640.

Crispin, J.C., Tsokos, G.C., 2010. IL-17 in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010, 1–4.

Cullen, S.P., Henry, C.M., Kearney, C.J., Logue, S.E., Feoktistova, M., Tynan, G.A., Lavrelis, E.C., Leverkus, M., Martin, S.J., 2013. Fas/CD95-induced chemokines can serve as “find-me” signals for apoptotic cells. Mol. Cell 49, 1034–1048.

Eriksson, C., Rantapaa-Dahlqvist, S., 2014. Cytokines in relation to autoantibodies before onset of symptoms for systemic lupus erythematosus. Lupus 23, 691–696.

Forster, R., Davalos-Misslitz, A.C., Rot, A., 2008. CCR7 and its ligands: balancing immunity and tolerance. Nat. Rev. Immunol. 8, 362–371.

Gabler, C., Kalden, J.R., Lorenz, H.M., 2003. The putative role of apoptosis-modified histones for the induction of autoimmunity in systemic lupus erythematosus. Biochem. Pharmacol. 66, 1441–1446.

Garrone, P., Neidhardt, E.M., Garcia, E., Galibert, L., van Kooten, C., Banchereau, J., 1995. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J. Exp. Med. 182, 1265–1273.

Genestier, L., Fournel, S., Flacher, M., Assoussou, O., Revillard, J.P., Bonnefoy-Berard, N., 1998. Induction of Fas (Ap0-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 91, 2360–2368.

Gordon, C., Matthews, N., Schlesinger, B.C., Akbar, A.N., Bacon, P.A., Emery, P., Salmon, M., 1996. Active systemic lupus erythematosus is associated with the recruitment of naive/resting T cells. Br. J. Rheumatol. 35, 226–230.

Kuwabara, T., Ishikawa, F., Yasuda, T., Arimoto, K., Nakano, H., Tanaka, Y., Okada, Y., Lipp, M., Kakiuchi, T., 2009. CCR7 ligands are required for development of experimental autoimmune encephalomyelitis through generating IL-23-dependent Th17 cells. J. Immunol. 183, 2513–2521.

Leiva, L.E., Monjure, H., Sorensen, R.U., 2013. Recurrent respiratory infections, specific antibody deficiencies, and memory B cells. J. Clin. Immunol. 33 (Suppl. 1), S57–S61.

Liu, X.K., Lin, X., Gaflan, S.L., 2004. Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17. J. Biol. Chem. 279, 52762–52771.

MacLennan, I.C., 1994. Germinal centers. Annu. Rev. Immunol. 12, 117–139.

Okada, T., Cyster, J.G., 2006. B cell migration and interactions in the early phase of antibody responses. Curr. Opin. Immunol. 18, 278–285.

Rana, A., Minz, R.W., Aggarwal, R., Anand, S., Pasricha, N., Singh, S., 2012. Gene expression of cytokines (TNF-alpha, IFN-gamma), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus 21, 1105–1112.

Rensing-Ehl, A., Hess, S., Ziegler-Heitbrook, H.W., Riethmuller, G., Engelmann, H., 1995. Fas/Apo-1 activates nuclear factor kappa B and induces interleukin-6 production. J. Inflamm. 45, 161–174.

Sallusto, F., Lenig, D., Forster, R., Lipp, M., Lanzevacchcia, A., 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708–712.

Sallusto, F., Mackay, C.R., Lanzavecchia, A., 2000. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18, 593–620.

Sallusto, F., Lenig, D., Forster, R., Lipp, M., Lanzevacchcia, A., 2014. Pillars article: two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999. 401: 708–712. J. Immunol. 192, 840–844.

Shah, D., Aggarwal, A., Bhatnagar, A., Kiran, R., Wanchu, A., 2011. Association between T lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative stress in systemic lupus erythematosus. Free Radic. Res. 45, 559–567.

Silvestris, V., Williams, R.C., Calvani, N., Grinello, D., Tucci, M., Cafforio, P., Dammacco, F., 2002. Serum elevations of soluble Fas (CD95) in patients with systemic lupus erythematosus. Clin. Lab. 285, 276, 581–593.

Tyrrell-Price, J., Lydyard, P.M., Isenberg, D.A., 2001. The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus. Clin. Exp. Immunol. 124, 118–125.

Ugarte-Gil, M.F., Sanchez-Zuniga, C., Gamboa-Cardenas, R.V., Aliaga-Zamudio, M., Zevallos, F., Tineo-Pozo, G., Cucho-Venegas, J.M., Mosquera-Riveros, A., Perich-Campos, R.A., Alfaro-Lozano, J.L., Medina, M., Rodriguez-Bellido, Z., Alarcon, G.S., Pastor-Asurza, C.A., 2014. Circulating naive and memory CD4+ T cells and metabolic syndrome in patients with systemic lupus erythematosus: data from a primarily Mestizo population. Rheumatology (Oxford) (in press).
Wen, Z., Xu, L., Xu, W., Xiong, S., 2012. Production of anti-double-stranded DNA antibodies in activated lymphocyte derived DNA induced lupus model was dependent on CD^4^+ T cells. Lupus 21, 508–516.

Xu, Q., Katakura, Y., Yamashita, M., Fang, S., Tamura, T., Matsumoto, S.E., Aiba, Y., Teruya, K., Osada, K., Nishikawa, R., Shirahata, S., 2004. IL-10 augments antibody production in in vitro immunized lymphocytes by inducing a Th2-type response and B cell maturation. Biosci. Biotechnol. Biochem. 68, 2279–2284.

Xue, C., Lan-Lan, W., Bei, C., Jie, C., Wei-Hua, F., 2006. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus. Cell. Immunol. 239, 121–128.